- Provides a synopsis of current clinical and basic research on neuroblastoma
- Presents the state of the art regarding tumor microenvironment and targeted therapeutics such as immunotherapy
- Edited and authored by recognized experts in the field
This book provides a state-of-the-art review of the biology, treatment, and other critical aspects of neuroblastoma, reflecting the dramatic advances that have been achieved in understanding and management.
Topics are arranged according to the book’s dominant themes of the “seed” (tumor genomics, epigenetics, metabolism, and stem cells) and the “soil” (tumor microenvironment, adaptive and innate immunity, and exosomes) and how both of these influences can serve as rich targets for intervention, whether by targeted molecular therapy or immunotherapy. Therapeutic strategies that are currently in use or under consideration for the future are discussed in detail, with the focus on precision medicine.
Further individual chapters are devoted to the biology and genetics of relapsed/refractory neuroblastoma and emerging methods of evaluating tumor burden. Finally, in keeping with the, albeit modest, increase in cure rates in high-risk disease, immune and cellular therapies are reviewed.
This coverage of what is becoming a not-so-enigmatic tumor will appeal to a broad readership including both experimental oncologists and clinicians who care for patients with neuroblastoma.
Table of ContentsEpidemiology, Presentation, and Evaluation
Pathology of Neuroblastoma
Genetic Predisposition
Part I: Evolving Concepts in Neuroblastoma Pathogenesis
Tumor Genomics: Copy Number Alterations
Tumor Genomics: Epigenetics
Tumor Genomics: Genomic Regulation
Tumor Metabolism
Part II: Evolving Concepts in Neuroblastoma Immunology and Tumor Microenvironment (Soil)
Neuroblastoma Tumor Microenvironment - Adaptive and Innate Immunity
Neuroblastoma Tumor Microenvironment - Non-Immune Cells and Exosomes
Part III: Evolving Concepts in Neuroblastoma Precision Medicine: Targeting the Seed and the Soil
Advances in evaluating tumor burden
Therapeutically Actionable Genetic Aberrations
Re-engaging the Immune System: Future of Immunotherapy
Future of Clinical Trials and Application of Precision Medicine
Summary and the Next 10 Years
